NHS labels Spinraza deal 'one of the most comprehensive in the world'
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Biogen’s (Nasdaq: BIIB) Spinraza (nusinersen) to treat infants, children and adults with spinal muscular atrophy (SMA).
It will be the first ever treatment for children with the rare muscle-wasting condition funded by National Health Service (NHS) England.
The NICE’s evaluation of Spinraza was based on the largest body of clinical evidence currently available across all types of SMA, with six years of data relating to more than 300 patients treated who had pre-symptomatic, infantile (type I) and later-onset (types II and III) SMA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze